Yüklüyor......
Sorafenib Inhibits Ribonucleotide Reductase Regulatory Subunit M2 (RRM2) in Hepatocellular Carcinoma Cells
The main curative treatments for hepatocellular carcinoma (HCC) are surgical resection and liver transplantation, which only benefits 15% to 25% of patients. In addition, HCC is highly refractory and resistant to cytotoxic chemotherapy. Although several multi-kinase inhibitors, such as sorafenib, re...
Kaydedildi:
| Yayımlandı: | Biomolecules |
|---|---|
| Asıl Yazarlar: | , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
MDPI
2020
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7022495/ https://ncbi.nlm.nih.gov/pubmed/31936661 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/biom10010117 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|